M. Cazzola et al., PREDICTION OF RESPONSE TO RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN ANEMIA OF MALIGNANCY, Haematologica, 81(5), 1996, pp. 434-441
Background. Since only a portion of anemic patients outside the uremia
setting benefit from erythropoietin treatment, a reliable means of pr
edicting potential responders and nonresponders would be very useful.
Materials and Methods. We retrospectively reviewed the clinical record
s of 58 patients with refractory anemia associated with various malign
ant disorders who had been treated with subcutaneous rHuEpo. The start
ing rHuEpo dose was 375 U/kg/week for 4 weeks, and was increased to 75
0 U/kg/week for another 4 weeks if no response was observed. Response
was defined as a Hb increase greater than or equal to 2 g/dL with no n
eed for blood transfusion. We examined the value of various laboratory
parameters (baseline levels, 2-week and 4-week changes) as predictors
of response. Endogenous erythropoietin production was evaluated by it
s serum level and erythroid activity was assessed through reticulocyte
count and circulating transferrin receptor. Results. Forty-eight indi
viduals were evaluable, 58% of whom responded to rHuEpo within 8 weeks
. Multiple regression analysis showed that 53% of the variation in the
8-week Hb concentration was explained by variations in baseline serum
erythropoietin and the 2-week change in serum transferrin receptor (p
< 0.001). Based on these two parameters, response prediction in indiv
idual patients would have resulted in a sensitivity of 96%, a specific
ity of 79% and an overall accuracy of 88%. In addition, 58% of the var
iation in the 8-week Hb was explained by variations in the 4-week chan
ges in Hb and reticulocyte count (p < 0.001). Utilizing these latter p
arameters and baseline serum erythropoietin, response prediction in in
dividual patients would have resulted in a sensitivity of 92%, a speci
ficity of 82% and an overall accuracy of 88%. Conclusions. This retros
pective analysis suggests that response to rHuEpo can be reasonably pr
edicted by pretreatment serum erythropoietin together with early chang
es in simple laboratory parameters.